{"id":4557,"date":"2026-07-08T15:38:18","date_gmt":"2026-07-08T15:38:18","guid":{"rendered":"https:\/\/bostonrelocationinsider.com\/?p=4557"},"modified":"2026-07-08T15:38:18","modified_gmt":"2026-07-08T15:38:18","slug":"prime-medicine-claims-victory-in-dispute-over-gene-editing-technology-with-beam-therapeutics","status":"publish","type":"post","link":"https:\/\/bostonrelocationinsider.com\/?p=4557","title":{"rendered":"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics"},"content":{"rendered":"
\n
\n

This story is republished from <\/i>STAT<\/i>, the health and medicine news site that\u2019s a partner to the Globe. Sign up for STAT\u2019s free Morning Rounds newsletter <\/i>here<\/i>.<\/i><\/span><\/p>\n

Read more Jayson Tatum breaks silence on Jaylen Brown trade: \u2018It\u2019s tough\u2019<\/a><\/p>\n

Prime Medicine said Wednesday that it had won an arbitration dispute against Beam Therapeutics, resolving for now a clash that had pitted two well-backed gene-editing companies that had been spun out of the same lab against each other.<\/span><\/p>\n

An arbitrator ruled that Prime\u2019s work on a gene-editing drug for the rare liver disease alpha-1 antitrypsin deficiency, or AATD, did not violate a 2019 agreement designed to prevent the two Cambridge-based companies from competing against one another.<\/span><\/p>\n<\/div>\n

\n

The ruling paves the way for Prime to start a clinical trial for AATD this quarter, lifting the biotech\u2019s stock 11 percent Wednesday morning. The outcome, however, is a blow to Beam Therapeutics.<\/span><\/p>\n

Beam\u2019s own AATD program is in late-stage development and could be the company\u2019s first blockbuster drug, but it has faced competition from a slew of competitors. Beam traded down roughly 2 percent.<\/span><\/p>\n

In a statement, Beam said it \u201crespectfully\u201d disagrees with the ruling but indicated it believed the fight may not be over. <\/span><\/p>\n

\u201cAs we have demonstrated with this process, we are and will continue to defend the innovative technologies, collaboration rights, and foundational patents in both base editing and prime editing that we have assembled,\u201d the company said. <\/span><\/p>\n

In an interview, Prime CEO Allan Reine described the dispute as being over \u2014 \u201cWe see this as binding arbitration,\u201d he said \u2014 and added that its conclusion positioned the company for more success. <\/span><\/p>\n

\u201cSo now we think we have the potential for two blockbusters,\u201d he said, referring to AATD and a program entering the clinic for Wilson\u2019s disease, a rare liver condition.<\/span><\/p>\n

The dispute arose over a year ago, when Prime announced it had secretly been working on an AATD program. <\/span><\/p>\n

AATD has become an increasingly hot target for CRISPR gene-editing companies, because it involves a single mutation in the liver \u2014 the easiest-to-reach organ with current gene-editing technology \u2014 and may affect around 100,000 people in the US, meaning any therapy could potentially bring in billions in revenue. <\/span><\/p>\n

Prime\u2019s decision was notable, however, because the company had seemingly handed over rights to work on AATD in 2019. Generally speaking, Prime and Beam were both built on cutting-edge gene-editing technology out of David Liu\u2019s lab at the Broad Institute.<\/span><\/p>\n

Read more Here\u2019s your World Cup forecast for Foxborough\u2019s final match Thursday<\/a><\/p>\n

Beam was launched first, to commercialize base editing, a technology that allows scientists to turn certain DNA letters into certain other DNA letters. That includes the single-letter switch required to treat most AATD patients.<\/span><\/p>\n

Prime came second, built around prime editing, a technology that allows scientists to turn any <\/i>DNA letter into any <\/i>other DNA letter, along with other changes. The tools overlapped. <\/span><\/p>\n

To prevent the two from competing, Prime and Beam struck a deal. Beam gave Prime, among other things, assistance on delivery technologies required to get gene editing into the body. <\/span><\/p>\n

And Prime gave Beam rights to use prime editing for any mutations that could already be treated with base editing. Prime would focus instead on a long list of diseases that could only be treated with prime editing. <\/span><\/p>\n

Most of those diseases, however, were either very rare or affected hard-to-reach organs. After Covid, as the biotech market tightened and enthusiasm for gene editing waned, Prime\u2019s stock tumbled.<\/span><\/p>\n

It shelved many of its original programs and soon after announced work on AATD. For technical reasons, it\u2019s possible that a prime-editing approach for AATD could be more effective. <\/span><\/p>\n

The company argued its work did not violate the earlier agreement because its treatment made changes to patients\u2019 DNA beyond the single-letter change strictly required to treat the disease. Beam disagreed.<\/span><\/p>\n

The ruling now puts Prime in a better position than it has been in some time. In addition to the AATD program, the company believes it will soon be able to snare approval for a treatment for the rare condition chronic granulomatous disease \u2014 thanks to striking early data and an immense amount of Food and Drug Administration flexibility \u2014 and has its treatment for Wilson\u2019s disease entering trials.<\/span><\/p>\n

The fight, however, around AATD and gene editing is far from over. In addition to the dispute with Beam, at least two other companies \u2014 CRISPR Therapeutics and Tessera Therapeutics \u2014 are working on treatments Prime believes are essentially copycats of its technology.<\/span><\/p>\n

\u201cWe\u2019re going to very vigorously defend our intellectual property at the right time,\u201d said Reine.<\/span><\/p>\n

Read more Boston\u2019s pro women\u2019s baseball team, set to begin play in August, has a name<\/a><\/p>\n

When was the right time?<\/span><\/p>\n

\u201cI\u2019m not going to comment further than that,\u201d he said.<\/span><\/p>\n<\/div>\n<\/article>\n","protected":false},"excerpt":{"rendered":"

A resolution in arbitration puts Prime in its best position in years.<\/p>\n","protected":false},"author":1,"featured_media":4556,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-4557","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"yoast_head":"\nPrime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics - Boston Relocation Insider<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bostonrelocationinsider.com\/?p=4557\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics - Boston Relocation Insider\" \/>\n<meta property=\"og:description\" content=\"A resolution in arbitration puts Prime in its best position in years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bostonrelocationinsider.com\/?p=4557\" \/>\n<meta property=\"og:site_name\" content=\"Boston Relocation Insider\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T15:38:18+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#\\\/schema\\\/person\\\/c08a982d5d5e7124cea9158df226037e\"},\"headline\":\"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics\",\"datePublished\":\"2026-07-08T15:38:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557\"},\"wordCount\":815,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/19d845587751ffd5cafd892b5452ff3b.avif\",\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557\",\"url\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557\",\"name\":\"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics - Boston Relocation Insider\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/19d845587751ffd5cafd892b5452ff3b.avif\",\"datePublished\":\"2026-07-08T15:38:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#\\\/schema\\\/person\\\/c08a982d5d5e7124cea9158df226037e\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557#primaryimage\",\"url\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/19d845587751ffd5cafd892b5452ff3b.avif\",\"contentUrl\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/19d845587751ffd5cafd892b5452ff3b.avif\",\"width\":1440,\"height\":960},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=4557#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#website\",\"url\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/\",\"name\":\"Boston Relocation Insider\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#\\\/schema\\\/person\\\/c08a982d5d5e7124cea9158df226037e\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/bostonrelocationinsider.com\"],\"url\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics - Boston Relocation Insider","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bostonrelocationinsider.com\/?p=4557","og_locale":"en_US","og_type":"article","og_title":"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics - Boston Relocation Insider","og_description":"A resolution in arbitration puts Prime in its best position in years.","og_url":"https:\/\/bostonrelocationinsider.com\/?p=4557","og_site_name":"Boston Relocation Insider","article_published_time":"2026-07-08T15:38:18+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bostonrelocationinsider.com\/?p=4557#article","isPartOf":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=4557"},"author":{"name":"admin","@id":"https:\/\/bostonrelocationinsider.com\/#\/schema\/person\/c08a982d5d5e7124cea9158df226037e"},"headline":"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics","datePublished":"2026-07-08T15:38:18+00:00","mainEntityOfPage":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=4557"},"wordCount":815,"commentCount":0,"image":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=4557#primaryimage"},"thumbnailUrl":"https:\/\/bostonrelocationinsider.com\/wp-content\/uploads\/2026\/07\/19d845587751ffd5cafd892b5452ff3b.avif","articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/bostonrelocationinsider.com\/?p=4557#respond"]}]},{"@type":"WebPage","@id":"https:\/\/bostonrelocationinsider.com\/?p=4557","url":"https:\/\/bostonrelocationinsider.com\/?p=4557","name":"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics - Boston Relocation Insider","isPartOf":{"@id":"https:\/\/bostonrelocationinsider.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=4557#primaryimage"},"image":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=4557#primaryimage"},"thumbnailUrl":"https:\/\/bostonrelocationinsider.com\/wp-content\/uploads\/2026\/07\/19d845587751ffd5cafd892b5452ff3b.avif","datePublished":"2026-07-08T15:38:18+00:00","author":{"@id":"https:\/\/bostonrelocationinsider.com\/#\/schema\/person\/c08a982d5d5e7124cea9158df226037e"},"breadcrumb":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=4557#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bostonrelocationinsider.com\/?p=4557"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bostonrelocationinsider.com\/?p=4557#primaryimage","url":"https:\/\/bostonrelocationinsider.com\/wp-content\/uploads\/2026\/07\/19d845587751ffd5cafd892b5452ff3b.avif","contentUrl":"https:\/\/bostonrelocationinsider.com\/wp-content\/uploads\/2026\/07\/19d845587751ffd5cafd892b5452ff3b.avif","width":1440,"height":960},{"@type":"BreadcrumbList","@id":"https:\/\/bostonrelocationinsider.com\/?p=4557#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bostonrelocationinsider.com\/"},{"@type":"ListItem","position":2,"name":"Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/bostonrelocationinsider.com\/#website","url":"https:\/\/bostonrelocationinsider.com\/","name":"Boston Relocation Insider","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bostonrelocationinsider.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bostonrelocationinsider.com\/#\/schema\/person\/c08a982d5d5e7124cea9158df226037e","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/bostonrelocationinsider.com"],"url":"https:\/\/bostonrelocationinsider.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/posts\/4557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4557"}],"version-history":[{"count":0,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/posts\/4557\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/media\/4556"}],"wp:attachment":[{"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}